InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.38
(
0.00%
)
US TECH 100
20,476.40
(
-0.07%
)
Dow Jones
43,958.19
(
0.00%
)
Brent Oil
72.92
(
1.47%
)
Bitcoin
90,809.57
(
0.27%
)
Post# of 253594
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120719
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: urche post# 36768

Friday, 12/01/2006 2:29:48 PM

Friday, December 01, 2006 2:29:48 PM

Post# of 253594
What became of Esperion?

From the Q&A session of PFE’s R&D webcast yesterday:

“…a small biotech company like Esperion doesn’t necessarily have the resources to do all the things that are needed to get things ready for long-term trials… The synthesis and the analytics around the material that they had available at that time really weren’t robust enough for us to be able to start phase-3. So we’ve had to go back and do a lot of work around that. I think we’ve pretty much figured all that out and solved those problems… We hope to move into phase-2b studies in the next year.”
—John LaMattina, President, Pfizer R&D

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up